info@mail.ucallm.com
From Synaptic Communication to Neural Circuit Function — Empowering Comprehensive Neurotransmission Profiling with Validated Antibody Solutions
Neurotransmission is the fundamental molecular process that enables neuronal communication, information processing, behavior regulation, and maintenance of brain homeostasis. Precise coordination of neurotransmitter synthesis, vesicular storage, synaptic release, receptor activation, and signal termination ensures dynamic regulation of neuronal networks and adaptive responses to environmental stimuli.
Beyond neurotransmitter release itself, neural communication relies on highly organized molecular systems involving:
Neurotransmitter synthesis enzymes controlling chemical messenger production
Transporter systems regulating neurotransmitter uptake, recycling, and clearance
Vesicular machinery mediating neurotransmitter packaging and release
Ionotropic receptors driving rapid synaptic excitation and inhibition
G protein-coupled receptors (GPCRs) regulating neuromodulatory signaling
Intracellular signaling pathways controlling neuronal adaptation and plasticity
Synaptic remodeling mechanisms underlying learning, memory, and neurological function
We provide comprehensive antibody solutions for investigating neurotransmission biology—from neurotransmitter metabolism and transporter regulation to receptor signaling, synaptic organization, neural circuit modulation, and disease-associated mechanisms.
Validated antibody solutions enable researchers to characterize:
Neurotransmitter synthesis and metabolic pathways
Transporter-mediated neurotransmitter recycling mechanisms
Presynaptic vesicle dynamics and synaptic release machinery
Excitatory and inhibitory neurotransmission balance
Receptor localization, activation, and downstream signaling
Synaptic plasticity and neuronal adaptation
Molecular mechanisms underlying neurological and psychiatric disorders
Neurotransmission & Receptor Transporter Biomarker Antibody Portfolio
——Comprehensive Solutions for Neurochemical Signaling, Synaptic Communication, and Neural Circuit Research
Neuronal communication depends on precisely coordinated interactions between neurotransmitter metabolism, transporter regulation, vesicular trafficking, receptor activation, and intracellular signaling pathways.Our validated antibody portfolio targets key molecular components involved in:
Research Focus | Representative Biomarkers | Research Applications |
Neurotransmitter Synthesis & Metabolism | TH, TPH2, ChAT, GAD65/GAD67, MAOA, COMT | Analysis of dopamine, serotonin, acetylcholine, and GABA synthesis pathways |
Neurotransmitter Transporter Systems | DAT/SLC6A3, NET/SLC6A2, SERT/SLC6A4, GAT1/SLC6A1, GlyT1/SLC6A9 | Investigation of neurotransmitter uptake, recycling, and synaptic clearance |
Vesicular Neurotransmitter Packaging | VMAT2/SLC18A2, VAChT/SLC18A3, VGLUT1-3/SLC17A7-9 | Characterization of neurotransmitter storage, vesicle loading, and presynaptic function |
Synaptic Vesicle Release Machinery | Synaptophysin, Synapsin I, SNAP25, STX1A, VAMP2 | Analysis of synaptic vesicle trafficking and neurotransmitter release |
Dopaminergic Signaling Network | TH, DAT, VMAT2, DRD1-DRD5, DARPP-32 | Investigation of reward circuitry, motor control, addiction, and Parkinson’s disease mechanisms |
Serotonergic Signaling Network | TPH2, SERT, HTR1A, HTR2A, HTR7 | Study of mood regulation, stress responses, and antidepressant mechanisms |
Adrenergic Signaling Pathway | NET, ADRA1A, ADRA2A, ADRB1, ADRB2 | Analysis of norepinephrine-mediated neuronal adaptation and stress signaling |
GABAergic Transmission | GAD65/GAD67, GABRA1 / GABRB2 / GABRG2, GABBR1 / GABBR2 Gephyrin | Investigation of inhibitory neurotransmission, neuronal excitability, and epilepsy mechanisms |
Glutamatergic Transmission | VGLUT1/2, GRIN1/GRIN2A/GRIN2B, GRIA1/GRIA2, mGluR1/5, PSD95 / DLG4. Homer1 | Analysis of excitatory signaling, synaptic plasticity, learning, and memory |
Cholinergic Signaling | ChAT, VAChT, CHRM1-5, CHRNA4,CHRNA7,CHRNB2 | Characterization of cognition, cortical signaling, and neurodegenerative mechanisms |
Presynaptic Vesicle Trafficking & Neurotransmitter Release | SYP/Synaptophysin, SYN1/Synapsin I, SV2A, SNAP25, STX1A, VAMP2, SYT1, RIMS1/2, CPLX1/2 | Characterization of synaptic vesicle trafficking, docking, priming, Ca²⁺-dependent vesicle fusion, and neurotransmitter release |
Neurotransmitter Receptor Signaling Network
—Comprehensive Antibody Solutions for Profiling Synaptic Communication, Neuronal Excitability, and Neural Circuit Regulation
Neurotransmitter receptors represent the molecular interface between extracellular chemical signals and neuronal responses. Through coordinated regulation of ion channels, GPCR signaling cascades, and synaptic remodeling pathways, receptor systems determine neuronal excitability, network activity, and adaptive plasticity.
Our validated receptor antibody panels enable comprehensive analysis of:
Fast excitatory and inhibitory synaptic transmission
Neuromodulatory receptor signaling
Synaptic plasticity mechanisms
Neuronal adaptation and circuit remodeling
Disease-associated receptor dysfunction
Research Focus | Key Markers | Research Applications |
Glutamatergic Receptor Signaling | NMDA receptors (GRIN1, GRIN2A, GRIN2B), AMPA receptors (GRIA1, GRIA2), mGluR1, mGluR5, Kainate receptors | Investigation of excitatory transmission, learning, memory formation, synaptic plasticity, and excitotoxicity |
GABAergic Receptor Signaling | GABA-A receptor subunits, GABA-B receptors, Gephyrin, GAD65/GAD67 | Analysis of inhibitory circuits, excitation–inhibition balance, epilepsy, and neural network stability |
Glycinergic Signaling | GlyT1 / SLC6A9,GlyT2 / SLC6A5,GLRA1,GLRA2,GLRB, Gephyrin |
|
Dopaminergic Receptor Signaling | DRD1-DRD5, TH, DAT, VMAT2, DARPP-32, CREB / p-CREB | Characterization of reward pathways, movement regulation, addiction, and Parkinson’s disease |
Serotonergic Receptor Signaling | HTR1A, HTR2A, HTR2C, HTR3A, HTR7 | Study of emotional regulation, psychiatric disorders, and antidepressant responses |
Adrenergic Receptor Signaling | ADRA1, ADRA2, ADRB1, ADRB2, CREB, ERK/MAPK pathway markers | Investigation of stress adaptation, autonomic regulation, and neuronal signaling responses |
Cholinergic Receptor Signaling | CHRM1-5, ChAT, VAChT, CHRNA4, CHRNA7, CHRNB2 | Research on cognition, memory, aging, and Alzheimer’s disease mechanisms |
Opioid Receptor Signaling | MOR/OPRM1, DOR/OPRD1, KOR/OPRK1 | Investigation of pain processing, reward circuits, addiction, and neural adaptation |
Featured Neurotransmission Research Panels
—Integrated Antibody Panels for Synaptic Function, Neural Circuit Mapping, and Disease Mechanism Discovery
Our comprehensive antibody panels enable researchers to systematically profile neurotransmission-associated pathways—from presynaptic neurotransmitter handling to postsynaptic signal integration, providing powerful tools for investigating neuronal function, synaptic plasticity, and neurological disease mechanisms.
n Neurotransmitter Synthesis & Homeostasis Panel—Profiling neurotransmitter production, metabolic regulation, and synaptic chemical homeostasis
TH | TPH2 | ChAT | GAD65 |
GAD67 | AADC | MAOA | COMT |
n Neurotransmitter Transport & Clearance Panel—Characterizing reuptake, extracellular clearance, and neuron–glia neurotransmitter homeostasis
DAT/SLC6A3 | NET/SLC6A2 | SERT/SLC6A4 | GAT1/SLC6A1 |
GAT3/SLC6A11 | GlyT1/SLC6A9 | EAAT1/SLC1A3 | EAAT2/SLC1A2 |
n Vesicular Loading & Presynaptic Release Panel—Mapping neurotransmitter packaging, vesicle trafficking, Ca²⁺-dependent release, and synaptic vesicle cycling
VMAT2/SLC18A2 | VAChT | VGLUT1/2 | Synaptophysin | SV2A |
Synapsin I | SNAP25 | VAMP2 | STX1A | SYT1 |
n Excitatory–Inhibitory Synaptic Signaling Panel—Profiling glutamatergic and GABAergic receptor systems underlying neuronal excitability and synaptic plasticity
GRIN1 | GRIN2A | GRIN2B | GRIA1/2 | GRM1 | GRM5 |
GABRA1 | GABRB2 | GABRG2 | GABBR1 | GABBR2 | Gephyrin |
n Synaptic Architecture & Plasticity Panel——Connecting neurotransmission with synaptic organization, activity-dependent signaling, and neuronal adaptation
PSD95 | Homer1 | Synaptophysin | Synapsin I | MAP2 |
CaMKII | CREB | p-CREB | BDNF | NeuN |
Why Researchers Choose Our Neurotransmission & Receptor Transporter Antibody Solutions
Validated Neural Targets. Integrated Synaptic Pathway Coverage. Mechanism-Driven Neuroscience Research.
Our validated antibody portfolio supports researchers in connecting neurotransmitter synthesis, transport, vesicular release, receptor activation, synaptic organization, and downstream signaling within an integrated experimental framework.
Research Challenge | Our Solution |
How can I characterize neurotransmitter synthesis and homeostasis? | TH, TPH2, ChAT, GAD65/GAD67 and neurotransmitter metabolism markers |
How can I analyze neurotransmitter uptake and clearance? | DAT, NET, SERT, GAT, GlyT and EAAT transporter solutions |
How can I investigate vesicular neurotransmitter loading? | VMAT2, VAChT and VGLUT1/2/3 vesicular transporter antibodies |
How can I characterize presynaptic neurotransmitter release? | Synaptophysin, SV2A, SNAP25, VAMP2, STX1A and SYT1 |
How can I profile excitatory and inhibitory neurotransmission? | NMDA, AMPA, mGluR, GABA-A/GABA-B and Gephyrin panels |
How can I investigate neuromodulatory signaling? | Dopamine, serotonin, adrenergic, cholinergic and opioid receptor solutions |
How can I study synaptic plasticity? | PSD95, Homer1, CaMKII, CREB/p-CREB and BDNF signaling markers |
How can I map neurotransmission in neural tissues? | IF/IHC and multiplex-compatible neuronal, synaptic, receptor and transporter antibodies |
How can I connect molecular changes with neurological disease mechanisms? | Integrated neurotransmitter, receptor, transporter and synaptic architecture panels |
Key reference
1. Shabareesh Pidathala, Shuyun Liao (2023). Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2. Nature. 2023 Nov;623(7989):1086-1092.
2. Tingyan Wu, Weili Cai (2023). Epigenetic regulation of neurotransmitter signaling in neurological disorders. Neurobiol Dis. 2023 Aug:184:106232.
3. Jiaxin Tan, Yuan Xiao (2024). Molecular basis of human noradrenaline transporter reuptake and inhibition. Nature. 2024 Aug;632(8026):921-929.
4. Heng Zhang, Yu-Ling Yin (2024). Dimerization and antidepressant recognition at noradrenaline transporter. Nature. 2024 Jun;630(8015):247-254.
5. Qiao Ma, Kunpeng Ma (2025). Binding mechanism and antagonism of the vesicular acetylcholine transporter VAChT. Nat Struct Mol Biol. 2025 May;32(5):818-827.
6. Changping Zhou, Guadalupe Segura-Covarrubias (2026). Cryo-EM structures of apo, agonist- and antagonist-bound heteromeric kainate receptors. Sci Adv. 2026 Jul 31;12(31):eady7558.
